TORONTO, Dec. 24, 2025 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. ("PharmAla" or the "Company") (CSE: MDMA) (OTC: MDXXF), a biotechnology company focused on the research, development, and manufacturing of LaNeo MDMA and novel derivatives of MDMA (MDXX class molecules), is pleased to have publicly filed its financial results for the periods ended August 31, 2025 and November 30th, respectively. All figures are reported in Canadian dollars. The Company's full set of Audited Financial Statements for the 2025 fiscal year, as well as its unaudited condensed interim consolidated financial statements for the first quarter of its 2026 fiscal year, and accompanying management's discussion and analysis can be accessed by visiting the Company's website at www.PharmAla.ca and its profile page on SEDAR+ at www.sedarplus.ca-
"Commencing in late 2025 and continuing into Q1 2026 we have taken major steps towards the development of our novel molecules and look to continue this momentum throughout the remainder of fiscal 2026 with the goal of commencing our Phase 2a/b clinical trial in Australia," said Nick Kadysh, CEO, PharmAla Biotech. "While we have been prioritizing our development, we have continued to see great traction in demand for our LaNeo MDMA, which has continued to grow our pipeline of clinical trial sales. With the approval of reimbursement for medical treatments using LaNeo MDMA in Australia, both by private medical insurers and by the Australian Department of Veterans Affairs ("DVA"), we believe that this trend will only continue."
Financial Highlights:
- Customer deposits have continued to grow consistently:
- Year End 2025 - an increase of $150k offset by recognized revenue of $83k, resulting in $276k compared to $209k as at August 31, 2025 and 2024, respectively.
- Q1 2026 - increase of $225k, offset by recognized revenue of $68k, resulting in $433k compared to $276k as at November 30, 2025 and August 31, 2025, respectively.
- These deposits, generally being 50% of the total contract value, can be recognized along with the remaining revenue when the related product is shipped, which for many customers requires the issuance of their clinical trial and/or import permits from relevant regulatory bodies.
"We have filed our short-form prospectus, secured a lending partner in Australia and have grown our clinical trial revenue pipeline and related customer deposits, all of which will help us to fund our clinical trial and development work," said Will Avery, CFO, PharmAla Biotech. "With these pieces in play we are excited for the growth we anticipate for PharmAla in the year ahead."
About PharmAla
PharmAla Biotech Holdings Inc. (CSE: MDMA) (OTCQB: MDXXF) is a biotechnology company focused on the research, development, and manufacturing of MDXX class molecules, including MDMA. PharmAla was founded with a dual focus: alleviating the global backlog of generic, clinical-grade MDMA to enable clinical trials as well as commercial sales in selected jurisdictions, and to develop novel drugs in the same class. PharmAla is the only company currently provisioning clinical-grade MDMA for patient treatments outside of clinical trials. PharmAla's research and development unit has completed proof-of-concept research into several IP families, including ALA-002, its lead drug candidate. PharmAla is a "regulatory first" organization, formed under the principle that true success in the psychedelics industry will only be achieved through excellent relationships with regulators.
For more information, please contact:
Nicholas Kadysh
Chief Executive Officer
PharmAla Biotech Holdings Inc.
Email: press@PharmAla.ca
Phone: 1-855-444-6362
Website: www.PharmAla.ca
Neither the CSE nor its Regulation Services Provider have reviewed or accept responsibility for the adequacy or accuracy of this release.
Cautionary Note Regarding Forward-Looking Statements
This press release contains "forward-looking statements" within the meaning of applicable securities laws. All statements contained herein that are not clearly historical in nature may constitute forward-looking statements. Generally, such forward-looking information or forward-looking statements can be identified by the use of forward-looking terminology such as "plans", "strategy", "expects" or "does not expect", "intends", "continues", "anticipates" or "does not anticipate", or "believes", or variations of such words and phrases or may contain statements that certain actions, events or results "will be taken", "will launch" or "will be launching", "will include", "will allow", "will be made" "will continue", "will occur" or "will be achieved". We direct readers to refer to the "Caution Regarding Forward-Looking Statements" contained within the Company's management's discussion and analysis for the period ended May 31, 2025, as filed on Sedar+ www.sedarplus.ca-
Readers are cautioned to not place undue reliance on forward-looking information. Actual results and developments may differ materially from those contemplated by these statements. Although the Company believes that the expectations reflected in these statements are reasonable, such statements are based on expectations, factors, and assumptions concerning future events which may prove to be inaccurate and are subject to numerous risks and uncertainties, certain of which are beyond the Company's control, including but not limited to the risk factors discussed in the Company's management's discussion and analysis, and elsewhere in this press release, as such factors may be further updated from time to time in our periodic filings, available at www.sedarplus.ca, which factors are incorporated herein by reference. Forward-looking statements contained in this press release are expressly qualified by this cautionary statement and reflect the Company's expectations as of the date hereof and are subject to change thereafter. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, estimates or opinions, future events or results, or otherwise, or to explain any material difference between subsequent actual events and such forward-looking information, except as required by applicable law.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in any state in which such offer, solicitation or sale would be unlawful. The securities being offered have not been, nor will they be, registered under the United States Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the United States Securities Act of 1933, as amended, and applicable state securities laws.
